On March 2025, Aspectus Pharma successfully hosted an informative webinar on the treatment of patients with chronic kidney disease (CKD). The event, which took place online attracted a healthcare professionals interested in the latest therapeutic approaches for CKD management.
The webinar began with a presentation by Aspectus Pharma, where attendees were introduced to the company and its medicines in the nephrology area. Special attention was given to Assevela (800 mg sevelamer carbonate) a key product for managing hyperphosphatemia – complication associated with CKD.
One of the highlights of the event was a lecture by Dr. Nikola Gjorgievski, Associate Professor and Director of the University Clinic of Nephrology. He provided an in-depth review of CKD, its treatment options, and the link between CKD and cardiovascular risks. He also discussed the importance of sevelamer carbonate in managing mineral and bone disorders associated with CKD.
Following this Dr. Maja Kulibrk-Nedelkovska, a nephrology specialist from Diaverum shared clinical experience with Assevela (sevelamer) in dialysis patients. She presented key efficacy indicators, clinical results and hospital protocols for integrating the drug into CKD treatment. Her presentation offered valuable insights into real-world applications and patient outcomes.
The event concluded with a Q&A session, where both speakers addressed participants inquiries regarding CKD treatment and sevelamer’s role in controlling hyperphosphatemia in patients who are on dialysis.
Aspectus Pharma continues its commitment to advancing medical knowledge and supporting healthcare. Stay tuned for upcoming events and initiatives aimed at improving patient care.